Ajinomoto Bio-Pharma Services vs Merck KGaA / MilliporeSigma (CDMO): CDMO Comparison
How does Ajinomoto Bio-Pharma Services compare to Merck KGaA / MilliporeSigma (CDMO) for Biologics manufacturing?
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Merck KGaA / MilliporeSigma (CDMO) on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Merck KGaA / MilliporeSigma (CDMO) has FDA inspections on record (2); Ajinomoto Bio-Pharma Services does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
- Ajinomoto Bio-Pharma Services maintains 1 MHRA / UK GMP certificate; Merck KGaA / MilliporeSigma (CDMO) does not.
- Merck KGaA / MilliporeSigma (CDMO) appears as a manufacturing partner on more matched clinical programs (22 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and Merck KGaA / MilliporeSigma (CDMO) qualify as Biologics manufacturers; Ajinomoto Bio-Pharma Services carries the higher composite Signal Score for Biologics programs in this comparison.
What to evaluate for Biologics programs
Both Ajinomoto Bio-Pharma Services and Merck KGaA / MilliporeSigma (CDMO) qualify as Biologics CDMOs. When choosing between them for Biologics programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Frequently asked: Ajinomoto Bio-Pharma Services vs Merck KGaA / MilliporeSigma (CDMO)
How does Ajinomoto Bio-Pharma Services compare to Merck KGaA / MilliporeSigma (CDMO) for Biologics manufacturing?
On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 86/100 and Merck KGaA / MilliporeSigma (CDMO) is 82/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 2 for Merck KGaA / MilliporeSigma (CDMO); European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 2 for Merck KGaA / MilliporeSigma (CDMO). Both are tracked in the CDMO Signal directory as Biologics CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Merck KGaA / MilliporeSigma (CDMO)?
Both Ajinomoto Bio-Pharma Services and Merck KGaA / MilliporeSigma (CDMO) maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Merck KGaA / MilliporeSigma (CDMO) has 2.
How do Ajinomoto Bio-Pharma Services and Merck KGaA / MilliporeSigma (CDMO) compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Ajinomoto Bio-Pharma Services or Merck KGaA / MilliporeSigma (CDMO)?
Ajinomoto Bio-Pharma Services is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Merck KGaA / MilliporeSigma (CDMO) is matched to 22. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Biologics manufacturing — Ajinomoto Bio-Pharma Services or Merck KGaA / MilliporeSigma (CDMO)?
Both Ajinomoto Bio-Pharma Services and Merck KGaA / MilliporeSigma (CDMO) are tagged as Biologics CDMOs in our directory, so both are credible options for Biologics programs. The most important differentiator for Biologics selection is typically scale & bioreactor fit: Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →